Pune: Omicron now is the dominant SARS-COV-2 variant here, quickly replacing deltas in a little more than a month, the analysis of 1,769 samples sorted at the Institute of Education and Indian Science Research, and the National Chemical Laboratory has revealed.
Sequencing genomes in both institutions, between 28 November and January 8, found that Omicron in just 1% of the sample from November 28 to 4th but in the sample analyzed between January 2 and January 8, the variant was in 83% of the sample.
Scientists from two institutes said findings showed that new variants had spread in the community.
Data also suggested that most cases of Covid-19 reported at this time can be associated with Omicron, Dr.
Krishhanpal Karmodiya, Professor of Biology at Iiser, to Ti.
Omicron was present in 83% of samples sorted in Citydelta, meanwhile, it seemed to have lost its relationship to Pune, with only 0.004% of samples sorted in the last week (January 2-8) who reported Delta Sub 14% variants and reporting.
Experts say although Omicron sees the rapid spread, the silver layer is that he has replaced a more malignant Delta variant, which is associated with severe covid and a large number of inpatients during the second wave.
But scientists say the public needs to be careful.
“Omicron has the advantages of exponential growth that facilitates high transmission.
This virus property threatens to compensate for any assistance due to a less severe disease caused by this variant,” Dr.
Dhanasecementan Shanmugam, the main senior scientist and Coprincipal investigators on projects in NCL, to TII.
“Therefore, regardless of the variant, delta or omicron, the appropriate behavior of Covid will help pass through the current wave,” he said.
Dr.
Karmodiya from Iiser said, “Even though there is a reduced risk of severity, because there are many influential variables that affect the course of the disease, it makes it difficult to predict the results.” Dr.
Anu Raghunathan, the main senior scientist and the main researcher at NCL said, “Omicron variants Especially for the efficacy of antibody countermeasures due to the amount of mutation in a surge protein.
The concern is that antibodies in clinical use can lose efficacy to B.
1.
1.
529 Omicron variants.
“He added,” when the transmission rate and no unavoidable pause between infection and hospitalization, infection among a large number of populations ultimately bear the risk of unwanted results.
In the end not only the virus, but also the host and the environment that dictates results.
“Dr.
Sanjay Pujari, a member of the National Covid Task Force, said,” Omicron seems to cause mild illness in the majority of patients but can still be able to cause Bkan covid is severe in a population that is not vaccinated, some vaccination or vulnerable.
“